Plato Investment Management Ltd Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

Plato Investment Management Ltd bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 999 shares of the company’s stock, valued at approximately $42,000.

Other institutional investors have also added to or reduced their stakes in the company. Capstone Investment Advisors LLC bought a new position in Janux Therapeutics in the 1st quarter worth about $1,969,000. Janus Henderson Group PLC boosted its holdings in shares of Janux Therapeutics by 1.8% in the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after purchasing an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Janux Therapeutics in the 1st quarter worth about $739,000. Virtu Financial LLC purchased a new position in shares of Janux Therapeutics in the 1st quarter worth about $609,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after purchasing an additional 378,477 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00. Following the completion of the transaction, the insider now owns 2,959,175 shares of the company’s stock, valued at approximately $139,081,225. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 268,578 shares of company stock worth $12,071,151. 35.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JANX shares. HC Wainwright reiterated a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a report on Monday, August 19th. Scotiabank dropped their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Wedbush restated an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus assumed coverage on Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a report on Monday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $66.13.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $49.89 on Tuesday. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $65.60. The stock has a 50 day simple moving average of $42.99 and a two-hundred day simple moving average of $44.15. The stock has a market cap of $2.59 billion, a P/E ratio of -40.89 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. The business’s revenue for the quarter was up 709.1% on a year-over-year basis. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.